Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Pierre Sesques, Roch Houot, Yassine Al Tabaa, Fabien Le Bras, Loic Ysebaert, Sylvain Choquet, Vincent Camus, Jacques-Olivier Bay, François-Xavier Gros, Franck Morschhauser, Olivier Casasnovas, Thomas Gastinne, Catherine Thieblemont, Magalie Joris, Laure Ricard, Caroline Regny, Laurianne Drieu La Rochelle, Pierre Feugier, Ambroise Marçais, Isabelle Chaillol, Karin Tarte, Camille Laurent, Guillaume Cartron
Institutions: Hospices Civils de Lyon, Hôpital Pontchaillou, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Henri-Mondor, Institut universitaire du cancer de Toulouse Oncopole, Pitié-Salpêtrière Hospital, Centre Henri Becquerel, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre Hospitalier Universitaire de Bordeaux, Hôpital Claude Huriez, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Nantes, Hôpital Saint-Louis, Centre Hospitalier Universitaire Amiens-Picardie, Hôpital Saint-Antoine, Hôpital Albert Michallon, Centre Hospitalier Universitaire de Tours, Centre Hospitalier Régional et Universitaire de Nancy, Hôpital Necker-Enfants Malades, The Lymphoma Academic Research Organisation, Centre Hospitalier Universitaire de Montpellier
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417005989
Cites:
Cited by:
Related to: